Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Biochip for assisting large intestine cancer targeted therapy

A targeted therapy and biochip technology, applied in the field of biomedicine, can solve problems such as low sensitivity, high cost, and limited accuracy, and achieve the effects of accurate prediction of curative effect, excellent performance, and high sensitivity

Inactive Publication Date: 2014-04-02
吴兴新
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, studies have shown that even in patients with KRAS wild type obtained by KRAS genotyping, more than 64% of patients still cannot achieve effective remission
The main disadvantages are as follows: 1. The accuracy of single KRAS typing to guide targeted therapy of colorectal cancer is low; 2. Common genotype analysis by polymerase chain reaction is time-consuming, low in sensitivity, and has limited accuracy. Under certain circumstances, the number of DNA mutation sites is limited and the cost is high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Biochip for assisting large intestine cancer targeted therapy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: Comparison of the remission rate of colorectal cancer treated with Erbitux on the basis of standard first-line chemotherapy with different classification methods. Compared with single KRAS typing, the multi-site typing of the present invention can improve the remission rate of Erbitux for individualized treatment of colorectal cancer.

[0023]

Embodiment 2

[0024] Example 2: Colorectal cancer patient 5001, male, 43 years old, was treated with Erbitux combined with irinotecan, and received two chemotherapy oxaliplatin and fluoropyrimidine before. The genotype detected by the chip of the present invention is KRASc. (34G; 35G; 38G; ​​175G; 181C; 182A; 183A; 436G); BRAFc. (1799T; 1801A; 1742A; 1397G; 1406G; 1405G); 35G; 37G; 181C; 182A; 183A); PIK3CAc. (3012G; 3019G; 3140A; 3145G).

[0025] Using the multi-site analysis of the present invention, the patient's colorectal cancer remission rate was 41%, the disease control rate was 82%, the median progression-free survival period (29 weeks, range 24-32 weeks) and median survival period (54 weeks , range 48-59 weeks)

[0026] Using a single KRAS analysis, the patient's colorectal cancer response rate was 36%, the disease control rate was 76%, and the median progression-free survival (24 weeks, range 24-29 weeks) and median survival (49 weeks, range 44 -55 weeks)

[0027] In fact, the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention discloses a biochip for assisting large intestine cancer targeted therapy. Meanwhile, the present invention further discloses a use method of the biochip and a preparation method for a bio-chip detection sample. According to the present invention, multiple gene loci can be simultaneously detected, such that the biochip of the present invention has characteristics of excellent performance and exact treatment effect prediction compared with the traditional single-detection K-RAS mutation chip, the large intestine cancer treatment remission rate of Erbitux can be increased to 41% from 36%, and the disease control rate can be increased to 82% from 76%; and due to use of immune microarray detection, advantages of short time consuming, high sensitivity, high accuracy, high throughput, and low cost of individual detection are provided.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to a biochip for assisting targeted therapy of colorectal cancer, a method for using the biochip, and a method for preparing a detection sample. Background technique [0002] At present, KRAS genotyping is mainly used to assist targeted therapy of colorectal cancer. KRAS genotyping can significantly improve the response rate of colorectal cancer treated with Erbitux on the basis of standard first-line chemotherapy, and the overall survival of patients is also significantly prolonged. However, studies have shown that more than 64% of patients with KRAS wild type obtained through KRAS genotyping still cannot achieve effective remission. The main disadvantages are as follows: 1. The accuracy of single KRAS typing to guide targeted therapy of colorectal cancer is low; 2. Common genotype analysis by polymerase chain reaction is time-consuming, low in sensitivity, and has limited a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68
CPCC12Q1/6886C12Q2600/156
Inventor 吴兴新
Owner 吴兴新
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com